Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)
Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)
Johns Hopkins University
40 participants
Sep 17, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to assess the safety and effectiveness of co-administered MDMA and psilocybin in military Veterans with a diagnosis of Posttraumatic Stress Disorder (PTSD). To apply or learn more, please view our website: https://hopkinspsychedelic.org/pamvet
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Experimental Psilocybin (exact dosages not disclosed)
Comparator Psilocybin (exact dosages not disclosed)
Experimental MDMA (exact dosages not disclosed)
Comparator MDMA (exact dosages not disclosed)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06989957